Cargando…

A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group

BACKGROUND: Postoperative adhesions occur when fibrous strands of internal scar tissue bind anatomical structures to one another. The most common cause of intra-abdominal adhesions is previous intra-abdominal surgical intervention. Up to 74% of intestinal obstructions are caused by post surgical adh...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Reinhold, Baumann, Petra, Jauch, Karl-Walter, Schmoor, Claudia, Weis, Christine, Odermatt, Erich, Knaebel, Hanns-Peter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912830/
https://www.ncbi.nlm.nih.gov/pubmed/20604918
http://dx.doi.org/10.1186/1471-2482-10-20
_version_ 1782184630721445888
author Lang, Reinhold
Baumann, Petra
Jauch, Karl-Walter
Schmoor, Claudia
Weis, Christine
Odermatt, Erich
Knaebel, Hanns-Peter
author_facet Lang, Reinhold
Baumann, Petra
Jauch, Karl-Walter
Schmoor, Claudia
Weis, Christine
Odermatt, Erich
Knaebel, Hanns-Peter
author_sort Lang, Reinhold
collection PubMed
description BACKGROUND: Postoperative adhesions occur when fibrous strands of internal scar tissue bind anatomical structures to one another. The most common cause of intra-abdominal adhesions is previous intra-abdominal surgical intervention. Up to 74% of intestinal obstructions are caused by post surgical adhesions. Although a variety of methods and agents have been investigated to prevent post surgical adhesions, the problem of peritoneal adhesions remains largely unsolved. Materials serving as an adhesion barrier are much needed. METHODS/DESIGN: This is a prospective, randomised, controlled, patient blinded and observer blinded, single centre phase I-II trial, which evaluates the safety of A-Part(® )Gel as an adhesion prophylaxis after major abdominal wall surgery, in comparison to an untreated control group. 60 patients undergoing an elective median laparotomy without prior abdominal surgery are randomly allocated into two groups of a 1:1- ratio. Safety parameter and primary endpoint of the study is the occurrence of wound healing impairment or peritonitis within 28 (+10) days after surgery. The frequency of anastomotic leakage within 28 days after operation, occurrence of adverse and serious adverse events during hospital stay up to 3 months and the rate of adhesions along the scar within 3 months are defined as secondary endpoints. After hospital discharge the investigator will examine the enrolled patients at 28 (+10) days and 3 months (±14 days) after surgery. DISCUSSION: This trial aims to assess, whether the intra-peritoneal application of A-Part(® )Gel is safe and efficacious in the prevention of post-surgical adhesions after median laparotomy, in comparison to untreated controls. TRIAL REGISTRATION: NCT00646412
format Text
id pubmed-2912830
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29128302010-07-31 A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group Lang, Reinhold Baumann, Petra Jauch, Karl-Walter Schmoor, Claudia Weis, Christine Odermatt, Erich Knaebel, Hanns-Peter BMC Surg Study Protocol BACKGROUND: Postoperative adhesions occur when fibrous strands of internal scar tissue bind anatomical structures to one another. The most common cause of intra-abdominal adhesions is previous intra-abdominal surgical intervention. Up to 74% of intestinal obstructions are caused by post surgical adhesions. Although a variety of methods and agents have been investigated to prevent post surgical adhesions, the problem of peritoneal adhesions remains largely unsolved. Materials serving as an adhesion barrier are much needed. METHODS/DESIGN: This is a prospective, randomised, controlled, patient blinded and observer blinded, single centre phase I-II trial, which evaluates the safety of A-Part(® )Gel as an adhesion prophylaxis after major abdominal wall surgery, in comparison to an untreated control group. 60 patients undergoing an elective median laparotomy without prior abdominal surgery are randomly allocated into two groups of a 1:1- ratio. Safety parameter and primary endpoint of the study is the occurrence of wound healing impairment or peritonitis within 28 (+10) days after surgery. The frequency of anastomotic leakage within 28 days after operation, occurrence of adverse and serious adverse events during hospital stay up to 3 months and the rate of adhesions along the scar within 3 months are defined as secondary endpoints. After hospital discharge the investigator will examine the enrolled patients at 28 (+10) days and 3 months (±14 days) after surgery. DISCUSSION: This trial aims to assess, whether the intra-peritoneal application of A-Part(® )Gel is safe and efficacious in the prevention of post-surgical adhesions after median laparotomy, in comparison to untreated controls. TRIAL REGISTRATION: NCT00646412 BioMed Central 2010-07-06 /pmc/articles/PMC2912830/ /pubmed/20604918 http://dx.doi.org/10.1186/1471-2482-10-20 Text en Copyright ©2010 Lang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Lang, Reinhold
Baumann, Petra
Jauch, Karl-Walter
Schmoor, Claudia
Weis, Christine
Odermatt, Erich
Knaebel, Hanns-Peter
A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group
title A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group
title_full A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group
title_fullStr A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group
title_full_unstemmed A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group
title_short A prospective, randomised, controlled, double-blind phase I-II clinical trial on the safety of A-Part(® )Gel as adhesion prophylaxis after major abdominal surgery versus non-treated group
title_sort prospective, randomised, controlled, double-blind phase i-ii clinical trial on the safety of a-part(® )gel as adhesion prophylaxis after major abdominal surgery versus non-treated group
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912830/
https://www.ncbi.nlm.nih.gov/pubmed/20604918
http://dx.doi.org/10.1186/1471-2482-10-20
work_keys_str_mv AT langreinhold aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT baumannpetra aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT jauchkarlwalter aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT schmoorclaudia aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT weischristine aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT odermatterich aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT knaebelhannspeter aprospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT langreinhold prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT baumannpetra prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT jauchkarlwalter prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT schmoorclaudia prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT weischristine prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT odermatterich prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup
AT knaebelhannspeter prospectiverandomisedcontrolleddoubleblindphaseiiiclinicaltrialonthesafetyofapartgelasadhesionprophylaxisaftermajorabdominalsurgeryversusnontreatedgroup